Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:11479223rdf:typepubmed:Citationlld:pubmed
pubmed-article:11479223lifeskim:mentionsumls-concept:C0007634lld:lifeskim
pubmed-article:11479223lifeskim:mentionsumls-concept:C0008109lld:lifeskim
pubmed-article:11479223lifeskim:mentionsumls-concept:C1522449lld:lifeskim
pubmed-article:11479223lifeskim:mentionsumls-concept:C0079427lld:lifeskim
pubmed-article:11479223lifeskim:mentionsumls-concept:C0017638lld:lifeskim
pubmed-article:11479223lifeskim:mentionsumls-concept:C0253023lld:lifeskim
pubmed-article:11479223lifeskim:mentionsumls-concept:C0079419lld:lifeskim
pubmed-article:11479223lifeskim:mentionsumls-concept:C0596988lld:lifeskim
pubmed-article:11479223lifeskim:mentionsumls-concept:C1325410lld:lifeskim
pubmed-article:11479223lifeskim:mentionsumls-concept:C0681205lld:lifeskim
pubmed-article:11479223lifeskim:mentionsumls-concept:C1550555lld:lifeskim
pubmed-article:11479223pubmed:issue15lld:pubmed
pubmed-article:11479223pubmed:dateCreated2001-7-31lld:pubmed
pubmed-article:11479223pubmed:abstractTextAdenoviral chimeric tumor suppressor 1 (CTS1) gene transfer was evaluated as a novel approach of somatic gene therapy for malignant glioma. CTS1 is an artificial p53-based gene designed to resist various pathways of p53 inactivation. Here, we report that an adenovirus encoding CTS1 (Ad-CTS1) induces growth arrest and loss of viability in all glioma cell lines examined, in the absence of specific cell cycle changes. In contrast, an adenovirus encoding wild-type p53 (Ad-p53) does not consistently induce apoptosis in the same cell lines. Electron microscopic analysis of Ad-CTS1-infected glioma cells reveals complex cytoplasmic pathology and delayed apoptotic changes. Ad-CTS1 induces prominent activation of various p53 target genes, including p21 and MDM-2, but has no relevant effects on BCL-2 family protein expression. Although Ad-CTS1 strongly enhances CD95 expression at the cell surface, endogenous CD95/CD95 ligand interactions do not mediate CTS1-induced cell death. This is because Ad-CTS1 promotes neither caspase activation nor mitochondrial cytochrome c release and because the caspase inhibitors, z-val-Ala-DL-Asp-fluoromethylketone (zVAD)-fmk or z-Ile-Glu-Thr-Asp- fluoromethylketone (z-IETD)-fmk, do not block CTS1-induced cell death. Ad-CTS1 synergizes with radiotherapy and CD95 ligand in killing glioma cells. In summary, Ad-CTS1 induces an unusual type of cell death that appears to be independent of BCL-2 family proteins, cytochrome c release, and caspases. CTS1 gene transfer is a promising strategy of somatic gene therapy for malignant glioma.lld:pubmed
pubmed-article:11479223pubmed:languageenglld:pubmed
pubmed-article:11479223pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11479223pubmed:citationSubsetIMlld:pubmed
pubmed-article:11479223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11479223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11479223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11479223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11479223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11479223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11479223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11479223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11479223pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:11479223pubmed:statusMEDLINElld:pubmed
pubmed-article:11479223pubmed:monthAuglld:pubmed
pubmed-article:11479223pubmed:issn0008-5472lld:pubmed
pubmed-article:11479223pubmed:authorpubmed-author:WellerMMlld:pubmed
pubmed-article:11479223pubmed:authorpubmed-author:WolburgHHlld:pubmed
pubmed-article:11479223pubmed:authorpubmed-author:KüglerSSlld:pubmed
pubmed-article:11479223pubmed:authorpubmed-author:SchulzJ BJBlld:pubmed
pubmed-article:11479223pubmed:authorpubmed-author:BährMMlld:pubmed
pubmed-article:11479223pubmed:authorpubmed-author:NaumannUUlld:pubmed
pubmed-article:11479223pubmed:authorpubmed-author:WickWWlld:pubmed
pubmed-article:11479223pubmed:authorpubmed-author:ConseillerEElld:pubmed
pubmed-article:11479223pubmed:authorpubmed-author:RascherGGlld:pubmed
pubmed-article:11479223pubmed:issnTypePrintlld:pubmed
pubmed-article:11479223pubmed:day1lld:pubmed
pubmed-article:11479223pubmed:volume61lld:pubmed
pubmed-article:11479223pubmed:ownerNLMlld:pubmed
pubmed-article:11479223pubmed:authorsCompleteYlld:pubmed
pubmed-article:11479223pubmed:pagination5833-42lld:pubmed
pubmed-article:11479223pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:11479223pubmed:meshHeadingpubmed-meshheading:11479223...lld:pubmed
pubmed-article:11479223pubmed:meshHeadingpubmed-meshheading:11479223...lld:pubmed
pubmed-article:11479223pubmed:meshHeadingpubmed-meshheading:11479223...lld:pubmed
pubmed-article:11479223pubmed:meshHeadingpubmed-meshheading:11479223...lld:pubmed
pubmed-article:11479223pubmed:meshHeadingpubmed-meshheading:11479223...lld:pubmed
pubmed-article:11479223pubmed:meshHeadingpubmed-meshheading:11479223...lld:pubmed
pubmed-article:11479223pubmed:meshHeadingpubmed-meshheading:11479223...lld:pubmed
pubmed-article:11479223pubmed:meshHeadingpubmed-meshheading:11479223...lld:pubmed
pubmed-article:11479223pubmed:meshHeadingpubmed-meshheading:11479223...lld:pubmed
pubmed-article:11479223pubmed:meshHeadingpubmed-meshheading:11479223...lld:pubmed
pubmed-article:11479223pubmed:meshHeadingpubmed-meshheading:11479223...lld:pubmed
pubmed-article:11479223pubmed:meshHeadingpubmed-meshheading:11479223...lld:pubmed
pubmed-article:11479223pubmed:meshHeadingpubmed-meshheading:11479223...lld:pubmed
pubmed-article:11479223pubmed:meshHeadingpubmed-meshheading:11479223...lld:pubmed
pubmed-article:11479223pubmed:meshHeadingpubmed-meshheading:11479223...lld:pubmed
pubmed-article:11479223pubmed:meshHeadingpubmed-meshheading:11479223...lld:pubmed
pubmed-article:11479223pubmed:meshHeadingpubmed-meshheading:11479223...lld:pubmed
pubmed-article:11479223pubmed:meshHeadingpubmed-meshheading:11479223...lld:pubmed
pubmed-article:11479223pubmed:meshHeadingpubmed-meshheading:11479223...lld:pubmed
pubmed-article:11479223pubmed:meshHeadingpubmed-meshheading:11479223...lld:pubmed
pubmed-article:11479223pubmed:year2001lld:pubmed
pubmed-article:11479223pubmed:articleTitleChimeric tumor suppressor 1, a p53-derived chimeric tumor suppressor gene, kills p53 mutant and p53 wild-type glioma cells in synergy with irradiation and CD95 ligand.lld:pubmed
pubmed-article:11479223pubmed:affiliationLaboratory of Molecular Neuro-Oncology, Department of Neurology, Institute of Pathology, University of Tübingen Medical School, Hoppe-Seyler-Strasse 3, 72076 Tübingen, Germany.lld:pubmed
pubmed-article:11479223pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:11479223pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11479223lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:11479223lld:pubmed